Fused Ring Compound, Pharmaceutical Composition Containing Same, and Use of Fused Ring Compound
Summary
The European Patent Office published patent application EP4509507A1 for Chengdu Hyperway Pharmaceuticals Co., Ltd. and Shenzhen Hyperway Pharmaceuticals Co., Ltd. covering a fused ring compound and pharmaceutical composition. The patent application includes IPC classifications for heterocyclic compounds (C07D) and pharmaceutical preparations (A61K), with therapeutic application in cancer treatment (A61P 35/00). The patent is designated across 31 European Contracting States including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.
What changed
The European Patent Office published patent application EP4509507A1 for a fused ring compound and pharmaceutical composition containing the same, filed jointly by Chengdu Hyperway Pharmaceuticals Co., Ltd. and Shenzhen Hyperway Pharmaceuticals Co., Ltd. The patent application claims heterocyclic compounds classified under C07D 471/00 and C07D 471/04, pharmaceutical formulations using A61K 31/517 and A61K 31/519, and therapeutic use for cancer treatment under A61P 35/00.
Pharmaceutical companies developing heterocyclic compounds or oncology therapies should monitor this patent for potential freedom-to-operate implications in the European market. The patent designation across 31 European states means validation could affect drug development programs in major pharmaceutical markets including Germany, France, UK, Italy, Spain, and the Netherlands. Companies may wish to evaluate licensing opportunities or design-around strategies for any competing fused ring compound programs.
What to do next
- Monitor for patent validation decisions in target markets
- Review freedom-to-operate for fused ring compounds in EU
- Assess licensing opportunities for oncology applications
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND
Publication EP4509507A1 Kind: A1 Apr 01, 2026
Applicants
Chengdu Hyperway Pharmaceuticals Co., Ltd., Shenzhen Hyperway Pharmaceuticals Co., Ltd.
Inventors
REN, Junfeng, LIU, Guanfeng, WU, Xiancai, LI, Shai, SONG, Zhiquan, YI, Shoubing, ZHUO, Guoqing, CHEN, Lin, YUAN, Chenguang, LI, Yingfu
IPC Classifications
C07D 471/00 20060101AFI20260224BHEP C07D 471/04 20060101ALI20260224BHEP A61K 31/517 20060101ALI20260224BHEP A61K 31/519 20060101ALI20260224BHEP A61P 35/00 20060101ALI20260224BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.